At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRVO CervoMed
Closed 06-26 16:00:00 EDT
3.49
+0.14
+4.18%
盘后3.41
-0.08-2.29%
19:55 EDT
High3.51Low3.22Vol382.56K
Open3.27D1 Closing3.35Amplitude8.66%
Mkt Cap47.21MTradable Cap17.22MTotal Shares13.53M
T/O1.29MT/O Rate7.75%Tradable Shares4.93M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

H.C. Wainwright Keeps Their Buy Rating on CervoMed (CRVO)
TIPRANKS  ·  06-25 20:56
H.C. Wainwright Keeps Their Buy Rating on CervoMed (CRVO)
CervoMed Closes $10 Million Stock Offering
MT Newswires Live  ·  06-23
CervoMed Closes $10 Million Stock Offering
CervoMed Raises $10 Million in Direct Offering
TIPRANKS  ·  06-23
CervoMed Raises $10 Million in Direct Offering
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced at-the-Market Under Nasdaq Rules
THOMSON REUTERS  ·  06-23
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced at-the-Market Under Nasdaq Rules
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
GlobeNewswire  ·  06-23
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
CervoMed prices USD 10 million registered direct stock offering at USD 4 per share
Reuters  ·  06-22
CervoMed prices USD 10 million registered direct stock offering at USD 4 per share
Top Midday Gainers
MT Newswires Live  ·  06-19
Top Midday Gainers
CervoMed Reports $10 Million Direct Offering of Shares
MT Newswires Live  ·  06-19
CervoMed Reports $10 Million Direct Offering of Shares
CervoMed announces $10M registered direct offering priced at-the-market
TIPRANKS  ·  06-19
CervoMed announces $10M registered direct offering priced at-the-market
CervoMed prices USD 10 million registered direct stock offering at USD 4 per share
Reuters  ·  06-19
CervoMed prices USD 10 million registered direct stock offering at USD 4 per share
CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced at-the-Market Under Nasdaq Rules
THOMSON REUTERS  ·  06-19
CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced at-the-Market Under Nasdaq Rules
CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
GlobeNewswire  ·  06-19
CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:11 AM
Reuters  ·  06-18
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:11 AM
CervoMed Gains New Patent for Neflamapimod Dementia Therapy
TIPRANKS  ·  06-18
CervoMed Gains New Patent for Neflamapimod Dementia Therapy
CervoMed Receives Notice of Allowance for Neflamapimod Patent in Dementia With Lewy Bodies
MT Newswires Live  ·  06-18
CervoMed Receives Notice of Allowance for Neflamapimod Patent in Dementia With Lewy Bodies
CervoMed - Patent Expected to Provide Ip Protection Into 2042
THOMSON REUTERS  ·  06-18
CervoMed - Patent Expected to Provide Ip Protection Into 2042
CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia With Lewy Body Patients Into 2042
THOMSON REUTERS  ·  06-18
CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia With Lewy Body Patients Into 2042
CervoMed wins U.S. patent allowance for neflamapimod use in pure Lewy body dementia into 2042
Reuters  ·  06-18
CervoMed wins U.S. patent allowance for neflamapimod use in pure Lewy body dementia into 2042
Top Midday Gainers
MT Newswires Live  ·  06-17
Top Midday Gainers
CervoMed Jumps 29% Pre-Bell After Reporting to SEC Insider Purchase Worth $3 Million Late Monday
MT Newswires Live  ·  06-16
CervoMed Jumps 29% Pre-Bell After Reporting to SEC Insider Purchase Worth $3 Million Late Monday

Introduction

Company Name.
CervoMed
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Issue price:
--